STI Stock Trade Intelligence
ATX

AMPLIA THERAPEUTICS LIMITED

Health Care · ASX:ATX
$0.1200
0.00%
Market cap
$62M
Turnover
$36,734
Last price
$0.1200
Day change
0.00%
Announcements
8
Range, past year
Open 0.150 · Low 0.049 · Now 0.120 · High 0.425
Open ATX in the full dashboard →
Charts, screener, momentum and signals across every ASX-listed code.

ATX momentum and trend analysis

Our analysis
Independent analysis generated by Stock Trade Intelligence as at 2026-09-29.
Momentum quality
17/100
Wyckoff phase
Accumulation2d
Trend stage
Neutral
1 Day
+0.0%
1 Week
-4.0%
1 Month
-11.1%
1 Year
-22.6%
RSI
34
Avg daily range
6.4%

AMPLIA THERAPEUTICS LIMITED scores 17 out of 100 for momentum quality, a reading rated very low confidence. The score weighs trend structure, price consistency, volume backing and how long the move has held, so a high reading means a sustained trend rather than a single large day. Its trend is currently classified as Neutral.

On the Wyckoff cycle it sits in Accumulation, where it has been for 2 trading days. The weekly timeframe reads Downtrend, which does not yet agree with the daily view.

Against the wider market it is currently underperforming and the institutional accumulation signal reads low.

Points to watch
  • 60d drawdown -22.6%
  • High volatility (ATR 6.4%)
  • Thin liquidity
  • Risk rating: High
  • Composite downside risk elevated
ATX appears on this screen:
ASX stocks in Wyckoff accumulationASX momentum stocks by trend qualityASX stocks breaking outASX stocks near 52-week highs

ATX announcements

Recent price-sensitive releases.
  • 2026-08-04 Amplia signs Collaboration and Supply Agreement with Lilly Progress Report
  • 2026-07-29 Quarterly Activities/Appendix 4C Cash Flow Report Commitments Test Entity - First Quarter Activity Report | Commitments Test Entity - First Quarter Cashflow Report
  • 2026-05-29 Preliminary Final Report and Annual Report YE 31 March 2026
  • 2026-05-19 Amplia Launches First Stage of Pivotal Narmafotinib Trial
  • 2026-05-08 Amplia and ANZGOG announce Ovarian Cancer Study
  • 2026-04-28 Quarterly Activities/Appendix 4C Cash Flow Report
Get the daily briefing The day's price-sensitive announcements, ranked by what actually moved, with our own momentum and cycle read on each.